# immunoglobulin A nephropathy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/immunoglobulin-a-nephropathy

> 7 upcoming FDA catalysts in immunoglobulin A nephropathy: povetacicept (VRTX) on November 30, 2026 (PDUFA date); povetacicept (VRTX) on Dec 2027 to Mar 2028 (topline data readout); povetacicept (VRTX) on December 2027 (primary completion); felzartamab (BIIB) on Aug to Nov 2028 (topline data readout); and 3 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for immunoglobulin A nephropathy?

7 upcoming FDA catalysts in immunoglobulin A nephropathy: povetacicept (VRTX) on November 30, 2026 (PDUFA date); povetacicept (VRTX) on Dec 2027 to Mar 2028 (topline data readout); povetacicept (VRTX) on December 2027 (primary completion); felzartamab (BIIB) on Aug to Nov 2028 (topline data readout); and 3 more. Press release filed with the SEC (EX-99): "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." [Calendar and source filings](https://sec-api.dev/indications/immunoglobulin-a-nephropathy)

Source: Press release filed with the SEC (EX-99), accession 0000875320-26-000287, https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm (retrieved 2026-11-12). Last confirmed 2026-11-13. Cite: https://sec-api.dev/indications/immunoglobulin-a-nephropathy#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2026 | [Povetacicept NDA/BLA acceptance](https://sec-api.dev/pdufa/povetacicept) | ZLAB | immunoglobulin A nephropathy | completed | "•Povetacicept (pove, APRIL/BAFF): In June 2026, Zai Lab partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm)) |
| November 30, 2026 | [Povetacicept PDUFA date](https://sec-api.dev/pdufa/povetacicept) | VRTX | immunoglobulin A nephropathy | scheduled | "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)) |
| Dec 2027 to Mar 2028 | [Povetacicept topline data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07890909 (A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12-12 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890909)) |
| December 2027 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07890909 (A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12-12 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07890909)) |
| Aug to Nov 2028 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy | scheduled | "NCT07889362 (A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08-13 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07889362)) |
| August 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy | scheduled | "NCT07889362 (A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08-13 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07889362)) |
| Dec 2029 to Mar 2030 | [Povetacicept topline data readout](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07807995 (A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807995)) |
| December 2029 | [Povetacicept primary completion](https://sec-api.dev/pdufa/povetacicept) | VRTX | Immunoglobulin A Nephropathy | scheduled | "NCT07807995 (A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807995)) |

## Drugs

- [Povetacicept](https://sec-api.dev/pdufa/povetacicept) (VRTX)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/immunoglobulin-a-nephropathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "immunoglobulin A nephropathy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/immunoglobulin-a-nephropathy

```bibtex
@misc{secapidev_indications_immunoglobulin_a_nephropathy_20261116,
  title        = {immunoglobulin A nephropathy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/immunoglobulin-a-nephropathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_immunoglobulin_a_nephropathy_20261116","title":"immunoglobulin A nephropathy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/immunoglobulin-a-nephropathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
